热门资讯> 正文
Aprea Treateutics GAAP每股收益-0.92美元
2024-03-26 20:05
- Aprea Therapeutics press release (NASDAQ:APRE): Q4 GAAP EPS of -$0.92.
- $21.6 million in cash and cash equivalents as of December 31, 2023
- Private placement financing in March 2024 raised upfront gross proceeds of approximately $16 million
More on Aprea Therapeutics
- Aprea Therapeutics announces private placement financing of up to $34M
- Seeking Alpha’s Quant Rating on Aprea Therapeutics
- Historical earnings data for Aprea Therapeutics
- Financial information for Aprea Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
